Product Images Duloxetine

This text describes the details of Duloxetine Hydrochloride USP, its dosage, storage, and other instructions. It also mentions the manufacturer, dosage guide, and precautions such as keeping it out of children's reach and not using it if the inner seal is missing or broken. The medicine comes in the form of 60 capsules containing enteric-coated pellets equivalent to 22.4 mg of Duloxetine Hydrochloride USP for treating depression, anxiety, and pain in adults. The test for the USP assay and organic impurities is pending.*

The text describes the contents of each capsule containing Duloxetine Hydrochloride USP equivalent to 30 mg Duloxetine. It advises dispensing in a tightly closed container and provides instructions for storage in a controlled temperature environment. Usage guidelines are not provided clearly, and the USP assay and Organic Impurities test are still pending. The medication guide should be provided to each patient. The text also includes other relevant details such as manufacturer and product code but does not provide any accompanying literature for dosage.*

This is a description of Duloxetine Hydrochloride USP, a medication capsule manufactured and marketed by Ajanta Pharma Limited. Each capsule contains 4.9 mg of Duloxetine Hydrochloride USP, an equivalent dosage of 40 mg Duloxetine, and is coated to prevent gastric irritation. The dosage guidelines are available in the accompanying literature and should be kept in a tightly closed container, out of reach of children. The capsules are currently undergoing USP Assay & Organic Impurities testing. They can be stored in temperatures ranging from 15° to 30°C (59° to 86°F). The product is sold in a package of 30 capsules with an NDC code of 27241-164-30.*

Duloxetine is available in the form of enteric-coated pellets of 67.3 mg which is equivalent to 60 mg Duloxetine Hydrochloride USP. The usual dose and other information are available in the accompanying literature. It should be kept in a tightly closed container and out of reach of children. USP Assay & Organic Impurities test is pending. It should be stored between 15°C to 30°C. It should not be used if the inner seal is missing or broken. The medication is marketed by Ajanta Pharma USA Inc. with the code No. MH/DRUGS/AD/018 and NDC 27241-099-03. It is made in India. The pharmacist should dispense the accompanying medication guide to each patient.*

This is a graphical representation of the proportion of patients with relapse for placebo and duloxetine treatments over a period of time after randomization. The x-axis shows the time from randomization to relapse in days and the y-axis represents the proportion of patients with relapse. The graph shows a comparison between the two treatments: placebo and duloxetine. The proportion of patients with relapse for both treatments is indicated by the different lines.*

The text seems to be a table showing the percentage of patients who improved after taking Duloxetine 60mg twice a day, Duloxetine 60mg once a day, Duloxetine 20mg once a day, and Placebo. Additionally, the table displays the percentage improvement in pain from baseline.*

This is a graph that compares the percentage of patients who showed improvement in their pain after taking either Duloxetine 60mg twice daily or Duloxetine 60mg once daily or a placebo. The graph shows that the group who took Duloxetine 60mg twice daily had the highest percentage of improvement, followed by the group who took Duloxetine 60mg once daily, and lastly, the placebo group showing the least percentage of improvement.*

The text describes a medical treatment for pain management using Duloxetine at 60/120 mg once per day. There is a chart indicating the percentage of improvement in pain from a baseline measurement. The rest of the text appears to include random characters and does not provide any additional meaningful information.*

This is a description of a clinical trial that studied the effect of Duloxetine 60 mg once daily on pain improvement compared to a placebo. The chart shows the percentage improvement in pain from baseline in patients taking Duloxetine compared to those taking a placebo. However, due to the poor quality of the text, some characters are not recognizable or not in English, making the text difficult to read and understand.*